Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Express Scripts
Harvard Business School

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD9977

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug AZD9977?

AZD9977 is an investigational drug.

There have been 9 clinical trials for AZD9977. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2015.

The most common disease conditions in clinical trials are Heart Failure and [disabled in preview]. The leading clinical trial sponsors are AstraZeneca, Parexel, and [disabled in preview].

There are two US patents protecting this investigational drug and twenty international patents.

Recent Clinical Trials for AZD9977
TitleSponsorPhase
A Single Center Study in Healthy Volunteers to Assess the Pharmacokinetics of AZD9977 When Administered Alone and With ItraconazoleAstraZenecaPhase 1
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male SubjectsAstraZenecaPhase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose AdministrationParexelPhase 1

See all AZD9977 clinical trials

Clinical Trial Summary for AZD9977

Top disease conditions for AZD9977
Top clinical trial sponsors for AZD9977

See all AZD9977 clinical trials

US Patents for AZD9977

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD9977   Start Trial Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD9977   Start Trial Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD9977

Drugname Country Document Number Estimated Expiration Related US Patent
AZD9977 Argentina 101036 2034-06-30   Start Trial
AZD9977 Australia 2015282450 2034-06-30   Start Trial
AZD9977 Canada 2953655 2034-06-30   Start Trial
AZD9977 China 106536491 2034-06-30   Start Trial
AZD9977 Denmark 3160948 2034-06-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Moodys
Medtronic
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.